{"content":"<li class=\"n-box-item date-title\" data-end=\"1494647999\" data-start=\"1494561600\" data-txt=\"Monday, December 23, 2019\">Friday, May 12, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3267084\" data-ts=\"1494628166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267084-pandora-reclaims-ground-on-passive-5_4-cohen-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora reclaims ground on passive 5.4% Cohen stake</a></h4><ul>   <li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) closed <font color='green'>up 3.4%</font> today after Steven Cohen's Point72 reported taking a passive stake in the music streamer.</li>    <li>In a <a href=\"https://www.sec.gov/Archives/edgar/data/1230276/000089914017000409/p20962838a.htm\" target=\"_blank\">13G filing</a>, Point72 and affiliates reported a 5.4% stake.</li>    <li>While passive, it makes Cohen's firm a key shareholder with catalysts on the way. Pandora reported a <a href=\"https://seekingalpha.com/news/3264804-pandora-minus-2-percent-results-kkr-investment-board-exits\" target=\"_blank\">$150M cash infusion coming from KKR</a> earlier this week, and said it expected to <a href=\"https://seekingalpha.com/news/3265216-pandora-trims-losses-belief-can-sell-30-days\" target=\"_blank\">find a buyer for the company within 30 days</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267084\" data-linked=\"Pandora reclaims ground on passive 5.4% Cohen stake\" data-tweet=\"$P - Pandora reclaims ground on passive 5.4% Cohen stake https://seekingalpha.com/news/3267084-pandora-reclaims-ground-on-passive-5_4-cohen-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3267084-pandora-reclaims-ground-on-passive-5_4-cohen-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267083\" data-ts=\"1494627382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QHC\" target=\"_blank\">QHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267083-quorum-health-to-sell-two-hospitals-in-tennessee\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quorum Health to sell two hospitals in Tennessee</a></h4><ul>   <li>Quorum Health (<a href=\"http://seekingalpha.com/symbol/QHC\" target=\"_blank\">QHC</a> <font color='red'>-2.5%</font>) has a definitive deal to <a href=\"https://seekingalpha.com/pr/16831961-quorum-health-corporation-announces-definitive-agreement-divest-two-hospitals-tennessee\" target=\"_blank\">divest two Tennessee hospitals</a>.</li>    <li>The company has an agreement to sell Henderson County Community Hospital (45 beds) and McKenzie Regional Hospital (45 beds) to SSH Tennessee.</li>    <li>Overall, Quorum Health runs a portfolio of 35 hospitals with about 3,400 licensed beds.</li>    <li>The sale is expected to close by Aug. 1.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267083\" data-linked=\"Quorum Health to sell two hospitals in Tennessee\" data-tweet=\"$QHC - Quorum Health to sell two hospitals in Tennessee https://seekingalpha.com/news/3267083-quorum-health-to-sell-two-hospitals-in-tennessee?source=tweet\" data-url=\"https://seekingalpha.com/news/3267083-quorum-health-to-sell-two-hospitals-in-tennessee\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267080\" data-ts=\"1494625498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267080-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='green'>+12.2%</font>. <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='green'>+7.5%</font>. <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='green'>+7.5%</font>. <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a> <font color='green'>+5.7%</font>. <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+5.4%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-2.8%</font>. <a href='https://seekingalpha.com/symbol/KBWD' title='PowerShares KBW High Dividend Yield Financial Portfolio ETF'>KBWD</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/KOL' title='VanEck Vectors Coal ETF'>KOL</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/EWA' title='iShares MSCI Australia ETF'>EWA</a> <font color='red'>-1.6%</font>. <a href='https://seekingalpha.com/symbol/IJS' title='iShares S&P Small-Cap 600 Value ETF'>IJS</a> <font color='red'>-1.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267080\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$GAZ-OLD $URA $GDXJ - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3267080-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3267080-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267078\" data-ts=\"1494624918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267078-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/WPG' title='Washington Prime Group, Inc.'>WPG</a> <font color='green'>+4.7%</font>. <a href='https://seekingalpha.com/symbol/STNG' title='Scorpio Tankers Inc.'>STNG</a> <font color='green'>+4.2%</font>. <a href='https://seekingalpha.com/symbol/PRTY' title='Party City Holdco, Inc.'>PRTY</a> <font color='green'>+2.3%</font>. <a href='https://seekingalpha.com/symbol/AT' title='Atlantic Power Corporation'>AT</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/UMC' title='United Microelectronics Corporation'>UMC</a> <font color='green'>+2.0%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='red'>-4.1%</font>. <a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='red'>-2.1%</font>. IPXL <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a> <font color='red'>-1.8%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-1.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267078\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$WPG $STNG $PRTY - After Hours Gainers / Losers https://seekingalpha.com/news/3267078-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3267078-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267071\" data-ts=\"1494623829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAR\" target=\"_blank\">CAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267071-avid-budgetminus-2_1-chief-financial-officer-resigns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avid Budget -2.1% as chief financial officer resigns</a></h4><ul>   <li>Avis Budget (<a href=\"http://seekingalpha.com/symbol/CAR\" target=\"_blank\">CAR</a> <font color='red'>-1.7%</font>) is another <font color='red'>2.1% lower</font> in postmarket trading after news that its president and chief financial officer, David Wyshner, is <a href=\"https://seekingalpha.com/pr/16831948-avis-budget-group-announces-resignation-david-wyshner-president-cfo\" target=\"_blank\">resigning</a>.</li>    <li>He'll pursue other opportunities, the company said. Wyshner has been CFO since 2006, and president since January 2016.</li>    <li>The company will appoint Martyn Smith as its interim CFO and search for a permanent one. Smith had served as finance director of the Avis Budget EMEA unit and of Avis Europe.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267071\" data-linked=\"Avid Budget -2.1% as chief financial officer resigns\" data-tweet=\"$CAR - Avid Budget -2.1% as chief financial officer resigns https://seekingalpha.com/news/3267071-avid-budgetminus-2_1-chief-financial-officer-resigns?source=tweet\" data-url=\"https://seekingalpha.com/news/3267071-avid-budgetminus-2_1-chief-financial-officer-resigns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267052\" data-ts=\"1494621014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267052-boeing-resumes-test-flights-of-737-max\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing resumes test flights of 737 MAX</a></h4><ul>   <li>Boeing (<a href=\"http://seekingalpha.com/symbol/BA\" target=\"_blank\">BA</a> <font color='red'>-0.4%</font>) has quickly <a href=\"http://www.reuters.com/article/us-boeing-737max-engine-idUSKBN1882RX\" target=\"_blank\">resumed test flights</a> of its $110M 737 MAX 8 planes just two days after it <a href=\"https://seekingalpha.com/news/3265985-boeing-slides-1_9-percent-737-max-flight-suspension\" target=\"_blank\">suspended all flights</a> to look into an engine issue.</li>    <li>Air safety regulators backed the resumption, the company says, and a 737 MAX 8 took off around 3:15 p.m. ET.</li>    <li>Engine maker CFM (a joint venture between General Electric (<a href=\"http://seekingalpha.com/symbol/GE\" target=\"_blank\">GE</a> <font color='red'>-2.1%</font>) and France's Safran (<a href=\"http://seekingalpha.com/symbol/SAFRY\" target=\"_blank\">SAFRY</a> <font color='green'>+2.1%</font>)) says flaws in the <a href=\"https://seekingalpha.com/news/3266423-737-max-engine-problem-design-issue\" target=\"_blank\">forging of a disc</a> in the engine could have led to cracks.</li>    <li>The news backs <a href=\"https://seekingalpha.com/news/3266003-boeing-737-max-issue-short-term-blip-cowen\" target=\"_blank\">Cowen's view from Wednesday</a> that the problem was \"easily correctable\" and ultimately wouldn't affect first deliveries planned for this month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267052\" data-linked=\"Boeing resumes test flights of 737 MAX\" data-tweet=\"$BA $BA $GE - Boeing resumes test flights of 737 MAX https://seekingalpha.com/news/3267052-boeing-resumes-test-flights-of-737-max?source=tweet\" data-url=\"https://seekingalpha.com/news/3267052-boeing-resumes-test-flights-of-737-max\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267027\" data-ts=\"1494617897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267027-europe-gives-antitrust-ok-to-broadcoms-5_9b-brocade-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Europe gives antitrust OK to Broadcom&#39;s $5.9B Brocade buyout</a></h4><ul>   <li>Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='green'>+1.7%</font>) has gotten conditional <a href=\"http://www.reuters.com/article/us-brocade-commns-m-a-broadcom-eu-idUSKBN1882DD\" target=\"_blank\">antitrust approval from Europe</a> for its acquisition of Brocade (<a href=\"http://seekingalpha.com/symbol/BRCD\" target=\"_blank\">BRCD</a> <font color='green'>+0.2%</font>).</li>    <li>The European Commission says that concessions Broadcom offered -- including cooperation with competitors in some areas, and protecting private information -- addressed its remaining concerns.</li>    <li>\"Broadcom committed to cooperate closely and in a timely manner with competing HBA (host bus adaptor) cards suppliers to achieve the same level of interoperability as that of its own HBA cards and to protect third party confidential information,\" the EC said in its statement.</li>    <li>Brocade agreed to a <a href=\"https://seekingalpha.com/news/3219640-brocade-sold-broadcom-5_9b\" target=\"_blank\">$5.9B buyout last November</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267027\" data-linked=\"Europe gives antitrust OK to Broadcom&#39;s $5.9B Brocade buyout\" data-tweet=\"$AVGO $AVGO $BRCD - Europe gives antitrust OK to Broadcom&#39;s $5.9B Brocade buyout https://seekingalpha.com/news/3267027-europe-gives-antitrust-ok-to-broadcoms-5_9b-brocade-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3267027-europe-gives-antitrust-ok-to-broadcoms-5_9b-brocade-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267026\" data-ts=\"1494617602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267026-whole-foods-gives-up-gains-bmo-explains-caution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whole Foods gives up gains; BMO explains caution</a></h4><ul><li>Whole Foods (WFM) enjoyed a sizable pop after meeting earnings estimates on Wednesday evening, and announcing board changes and a turnaround plan. It hasn't held, and following today's<font color='red'> 2.15% decline</font>&nbsp;to $36.23, the stock has made a round-trip back to its pre-report level.</li><li>Dutifully lifting her EPS and PT estimates to reflect the company's buyback plan and expense-cutting promises, <a href=\"http://www.barrons.com/articles/whole-foods-dont-count-your-chickens-1494615291\" target=\"_blank\">BMO's Kelly Bania nevertheless</a> still advises selling the stock.</li><li>The company's expectations for positive comp sales by the end of 2018, and 2% growth by 2020 hinge on the rollout of its Affinity program, says Bania. \"We believe it is early to extrapolate results from Affinity tests ,\" she says, noting they've been completed only in Phila, Dallas, and four 365 stores.</li><li>The tests, she says, captured data from just 200K people - less than 1% of WFM's customers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3266573-reactions-whole-foods-market-shakeup\" target=\"_blank\">Reactions to the Whole Foods Market shakeup</a> (May 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3267026\" data-linked=\"Whole Foods gives up gains; BMO explains caution\" data-tweet=\"$AMZN - Whole Foods gives up gains; BMO explains caution https://seekingalpha.com/news/3267026-whole-foods-gives-up-gains-bmo-explains-caution?source=tweet\" data-url=\"https://seekingalpha.com/news/3267026-whole-foods-gives-up-gains-bmo-explains-caution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267025\" data-ts=\"1494616982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLYC\" target=\"_blank\">GLYC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267025-glycomimetics-perks-up-ahead-of-development-update-shares-up-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GlycoMimetics perks up ahead of development update; shares up 24%</a></h4><ul><li>Thinly traded micro cap GlycoMimetics (<a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+23.8%</font>) shows some life ahead of next Thursday's conference call to <a href=\"https://seekingalpha.com/pr/16824476-glycomimetics-reports-program-updates-first-quarter-2017-results\" target=\"_blank\">update </a>investors on development programs.</li><li>Its lead product candidate is rivipansel (GMI-1070), currently in Phase 3 development by licensee Pfizer for the treatment of vaco-occlusive crisis.</li><li>Two early-stage studies assessing GMI-1271 are currently recruiting patients: a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02811822?term=glycomimetics&amp;rank=1\" target=\"_blank\">Phase 1</a> for the adjunctive treatment of multiple myeloma and a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02306291?term=glycomimetics&amp;rank=2\" target=\"_blank\">Phase 1</a> for the treatment (with chemo) of AML.</li><li>Another ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT02931214?term=glycomimetics&amp;rank=5\" target=\"_blank\">Phase 1</a> is evaluating the safety and pharmacokinetics of GMI-1359 in healthy volunteers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3267025\" data-linked=\"GlycoMimetics perks up ahead of development update; shares up 24%\" data-tweet=\"$GLYC - GlycoMimetics perks up ahead of development update; shares up 24% https://seekingalpha.com/news/3267025-glycomimetics-perks-up-ahead-of-development-update-shares-up-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3267025-glycomimetics-perks-up-ahead-of-development-update-shares-up-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267020\" data-ts=\"1494615749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTD\" target=\"_blank\">TTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267020-trade-desk-soaringplus-32_2-after-perfect-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trade Desk soaring, +32.2% after &#39;perfect&#39; earnings</a></h4><ul>   <li>Trade Desk (NASDAQ:<a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a>) has built on postmarket indications yesterday, <font color='green'>up 32.2%</font> today to new highs, after what Susquehanna called \"the <a href=\"https://seekingalpha.com/news/3266715-trade-desk-17-percent-hours-q1-revenue-beat-and-guidance-raise\" target=\"_blank\">perfect earnings report</a>.\"</li>    <li>The ad-tech firm is rapidly gaining share across programmatic advertising, the firm's Shyam Patil notes, and rapidly growing mobile ads as well, with international business scaling nicely. Patil raised Susquehanna's price target to $60 from $41, implying 50% upside from yesterday's close (but 13.8% upside from today's lofty price).</li>    <li>It's \"firing on all cylinders,\" outgrowing the industry and capturing incremental dollars, notes Jefferies' Brian Fitzgerald, who raised his price target to $57 from $41.</li>    <li>Meanwhile, Cantor Fitzgerald says Trade Desk's sunny outlook is \"likely still conservative,\" with visibility and momentum that could run throughout the year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3266614-trade-desk-beats-revenue\" target=\"_blank\">The Trade Desk beats on revenue</a> (May. 11 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267020\" data-linked=\"Trade Desk soaring, +32.2% after &#39;perfect&#39; earnings\" data-tweet=\"$TTD - Trade Desk soaring, +32.2% after &#39;perfect&#39; earnings https://seekingalpha.com/news/3267020-trade-desk-soaringplus-32_2-after-perfect-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3267020-trade-desk-soaringplus-32_2-after-perfect-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267019\" data-ts=\"1494615686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAG\" target=\"_blank\">AMAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267019-amag-pharma-gets-credit-rating-upgrade-sharesplus-1_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMAG Pharma gets credit rating upgrade; shares +1.8%</a></h4><ul><li>Changes in the company's capital structure improves the position of unsecured creditors in a loss, <a href=\"https://www.moodys.com/\" target=\"_blank\">says Moody's, boosting</a> the rating on AMAG's (<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color='green'>+1.8%</font>) senior notes to Ba3 from B3.</li><li>The corporate family rating &#40;CFR&#41; is affirmed at B2, with Moody's noting AMAG's small relative size and the risk of market share erosion for Makena from generics.</li></ul><div class=\"tiny-share-widget\" data-id=\"3267019\" data-linked=\"AMAG Pharma gets credit rating upgrade; shares +1.8%\" data-tweet=\"$AMAG - AMAG Pharma gets credit rating upgrade; shares +1.8% https://seekingalpha.com/news/3267019-amag-pharma-gets-credit-rating-upgrade-sharesplus-1_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3267019-amag-pharma-gets-credit-rating-upgrade-sharesplus-1_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267017\" data-ts=\"1494615633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267017-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/DRWI' title='DragonWave Inc.'>DRWI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/SOFO' title='Sonic Foundry, Inc.'>OTC:SOFO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267017\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$TTD $GSAT $DRWI - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3267017-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3267017-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267012\" data-ts=\"1494612897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267012-benign-briefing-papers-send-sarepta-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Benign&#39; briefing papers send Sarepta up more than 3%</a></h4><ul><li>The FDA's&nbsp;Pediatric Advisory Committee and Pediatric Ethics Subcommittee released briefing documents ahead of its vote for whether children with Duchenne Muscular Dystrophy in Sarepta&rsquo;s (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+3.3%</font>) placebo-controlled &ldquo;Essence&rdquo; study should be able to get ports for drug delivery.</li><li>Calling the docs \"relatively benign,\" William Blair's Tim Lugo says it's likely the May 18 vote will be mostly procedural.</li><li>via Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3267012\" data-linked=\"&#39;Benign&#39; briefing papers send Sarepta up more than 3%\" data-tweet=\"$SRPT - &#39;Benign&#39; briefing papers send Sarepta up more than 3% https://seekingalpha.com/news/3267012-benign-briefing-papers-send-sarepta-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3267012-benign-briefing-papers-send-sarepta-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267005\" data-ts=\"1494610147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASPS\" target=\"_blank\">ASPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267005-big-holder-adds-to-altisource-portfolio-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big holder adds to Altisource Portfolio stake</a></h4><ul><li>Deer Park Road Management discloses its <a href=\"https://seekingalpha.com/filing/3547863\" target=\"_blank\">purchase of another 52K</a> shares of Altisource Portfolio Solutions (<a href='https://seekingalpha.com/symbol/ASPS' title='Altisource Portfolio Solutions SA'>ASPS</a> <font color='green'>+5.5%</font>) on Wednesday, brining its stake in the company north of 2M shares vs. total float of 11.41M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3267005\" data-linked=\"Big holder adds to Altisource Portfolio stake\" data-tweet=\"$ASPS - Big holder adds to Altisource Portfolio stake https://seekingalpha.com/news/3267005-big-holder-adds-to-altisource-portfolio-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3267005-big-holder-adds-to-altisource-portfolio-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267004\" data-ts=\"1494610086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHKE\" target=\"_blank\">CHKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267004-post-earnings-pop-for-cherokee\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings pop for Cherokee</a></h4><ul> <li>Cherokee (<a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='green'>+10.9%</font>) jumps after topping estimates with its FQ4 report, helped by the contribution of the Hi-Tec business.</li> <li>Hi-Tec sales came in at $7.8M during the quarter, including $6.6M in indirect product sales related to distribution and government contracts.</li> <li>Adjusted EBITDA was $2.9M vs. $2.7M a year ago.</li> <li>\"Our spring 2017 multi-category launch for the Cherokee brand in the U.S. is underway; the first step in launching our most comprehensive assortment of Cherokee-branded adult and children apparel, accessories, footwear and home products in many years,\" says CEO Henry Stupp.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3267004\" data-linked=\"Post-earnings pop for Cherokee\" data-tweet=\"$CHKE $APEX - Post-earnings pop for Cherokee https://seekingalpha.com/news/3267004-post-earnings-pop-for-cherokee?source=tweet\" data-url=\"https://seekingalpha.com/news/3267004-post-earnings-pop-for-cherokee\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267003\" data-ts=\"1494609248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267003-buying-picks-up-in-synergy-after-ardelyxs-tenapanor-data-shares-ahead-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buying picks up in Synergy after Ardelyx&#39;s tenapanor data; shares ahead 11%</a></h4><ul><li>Money flow has turned positive in Synergy Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='green'>+10.8%</font>) albeit on modestly higher volume. Earlier today, would-be competitor Ardelyx (<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='red'>-36.7%</font>) announced positive late-stage data on IBS-C candidate tenapanor but with a 14.6% rate of diarrhea, higher that Trulance's 5% (data from studies in chronic ideopathic constipation).</li></ul><div class=\"tiny-share-widget\" data-id=\"3267003\" data-linked=\"Buying picks up in Synergy after Ardelyx&#39;s tenapanor data; shares ahead 11%\" data-tweet=\"$SGYP $SGYP-OLD $ARDX - Buying picks up in Synergy after Ardelyx&#39;s tenapanor data; shares ahead 11% https://seekingalpha.com/news/3267003-buying-picks-up-in-synergy-after-ardelyxs-tenapanor-data-shares-ahead-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3267003-buying-picks-up-in-synergy-after-ardelyxs-tenapanor-data-shares-ahead-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>78&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267002\" data-ts=\"1494608420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267002-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CORR' title='CorEnergy Infrastructure Trust'>CORR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-7%</font>. WAC <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3267002\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$MBI $PN $CORR - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3267002-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3267002-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3267000\" data-ts=\"1494608135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3267000-globalstar-jumps-17-on-report-of-sale-process\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar jumps 17% on report of sale process</a></h4><ul><li>The company is working with financial advisers on a potential sale, according to Bloomberg's Alex Sherman. Potential buyers would naturally be major wireless and cable companies.</li><li>The move comes following the big bidding war for Straight Path Communications (won this week by Verizon). Globalstar recently won U.S. approval to use its satellite airwaves for mobile broadband service.</li><li><a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a>&nbsp;<font color='green'>+17.3%</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3266247-wsj-verizon-wins-straight-path-sweepstakes-3_1b-buyout-deal\" target=\"_blank\">WSJ: Verizon wins Straight Path sweepstakes with $3.1B buyout deal</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3267000\" data-linked=\"Globalstar jumps 17% on report of sale process\" data-tweet=\"$GSAT - Globalstar jumps 17% on report of sale process https://seekingalpha.com/news/3267000-globalstar-jumps-17-on-report-of-sale-process?source=tweet\" data-url=\"https://seekingalpha.com/news/3267000-globalstar-jumps-17-on-report-of-sale-process\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266996\" data-ts=\"1494607310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266996-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/RELV' title='Reliv&#39; International, Inc.'>RELV</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-58%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/INFU' title='InfuSystem Holdings, Inc.'>INFU</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='red'>-20%</font>. SYMX <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='red'>-16%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266996\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$TTD $RELV $FORD - Midday Gainers / Losers https://seekingalpha.com/news/3266996-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3266996-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266994\" data-ts=\"1494606802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEG\" target=\"_blank\">KEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266994-day-two-of-post-earnings-losses-for-key-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Day two of post-earnings losses for Key Energy</a></h4><ul><li>In its<a href=\"https://seekingalpha.com/pr/16829559-key-energy-services-reports-first-quarter-2017-earnings\" target=\"_blank\"> first full quarter since emerging</a> from bankruptcy, Key Energy (<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a> <font color='red'>-6%</font>) on Wednesday night reported adjusted EBTIDA of negative $11M, and adjusted pretax loss of $39.7M or $1.97 per share.</li><li>Rig services revenue of $60.3M was down 2.4% from Q4; fluid management services revenue of $17.9M down 0.5%; coiled tubing services revenue of $5.3M down 30.3%; fishing and rental services revenue of $15.9M up 5.8%.</li><li>International revenue of $2.1M down 64.8%.</li><li>Excluding activity put off by a large customer in CA thanks to heavy rains, rig services revenue was up 8% from Q4.</li><li>Management is seeing increases in activity and additional traction on discount recovery thus far in Q2. The company expects to see Q2 revenue growth of 10% with strong incremental margins.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3266229-key-energy-services-eps-2_33\" target=\"_blank\">Key Energy Services EPS of -$2.33</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3266994\" data-linked=\"Day two of post-earnings losses for Key Energy\" data-tweet=\"$KEG - Day two of post-earnings losses for Key Energy https://seekingalpha.com/news/3266994-day-two-of-post-earnings-losses-for-key-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3266994-day-two-of-post-earnings-losses-for-key-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266990\" data-ts=\"1494605619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EC\" target=\"_blank\">EC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266990-ecopetrolplus-6-after-strong-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ecopetrol +6% after strong Q1</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16831309-b-ecopetrol-b-business-group-presents-first-quarter-2017-results\" target=\"_blank\">company reported Q1</a> net income of COP886B, well more than double that of a year ago. EBITDA of COP5.81T topped estimates for COP4.76T.</li><li>At work, of course, were higher oil and gas prices even as oil output slipped 3.3% thanks to attacks on fields. There was also the Cano Limon pipeline, which was out of operation for 47 days during Q1. Sales of COP 13.4T were shy of estimates for COP13.7T.</li><li><a href='https://seekingalpha.com/symbol/EC' title='Ecopetrol S.A.'>EC</a>&nbsp;<font color='green'>+6%</font></li><li>Source: <a href=\"https://seekingalpha.com/pr/16831309-b-ecopetrol-b-business-group-presents-first-quarter-2017-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3266990\" data-linked=\"Ecopetrol +6% after strong Q1\" data-tweet=\"$EC - Ecopetrol +6% after strong Q1 https://seekingalpha.com/news/3266990-ecopetrolplus-6-after-strong-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3266990-ecopetrolplus-6-after-strong-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266989\" data-ts=\"1494605271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNG\" target=\"_blank\">LNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266989-cheniere-in-extensive-talks-to-boost-lng-china-shipments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheniere in &#39;extensive&#39; talks to boost LNG China shipments</a></h4><ul>   <li>In the wake of a reported <a href=\"https://seekingalpha.com/news/3266763-wsj-u-s-china-reach-deal-expand-u-s-exports-including-lng\" target=\"_blank\">deal between the U.S. and China</a> on natural gas exports, Cheniere Energy (<a href=\"http://seekingalpha.com/symbol/LNG\" target=\"_blank\">LNG</a> <font color='green'>+4.4%</font>) says today it's in \"extensive\" talks to <a href=\"http://www.reuters.com/article/usa-china-trade-lng-idUSL1N1IE12B?feedType=RSS\" target=\"_blank\">boost its shipments to China</a>.</li>    <li>In a little over a year of exporting, Cheniere has sold nine cargoes to China on spot contracts, while the company is looking toward long-term contracts with the new deal done.</li>    <li>It's had extensive negotiations with the Chinese in the past month, a spokesman says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266989\" data-linked=\"Cheniere in &#39;extensive&#39; talks to boost LNG China shipments\" data-tweet=\"$LNG - Cheniere in &#39;extensive&#39; talks to boost LNG China shipments https://seekingalpha.com/news/3266989-cheniere-in-extensive-talks-to-boost-lng-china-shipments?source=tweet\" data-url=\"https://seekingalpha.com/news/3266989-cheniere-in-extensive-talks-to-boost-lng-china-shipments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266987\" data-ts=\"1494604865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266987-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RELV' title='Reliv&#39; International, Inc.'>RELV</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SYPR' title='Sypris Solutions, Inc.'>SYPR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KOSS' title='Koss Corporation'>KOSS</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266987\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$RELV $FORD $PME - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3266987-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3266987-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266978\" data-ts=\"1494602814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDI\" target=\"_blank\">GDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266978-gardner-denverplus-4-in-ipo-open\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gardner Denver +4% in IPO open</a></h4><ul> <li>Gardner Denver Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GDI' title='Gardner Denver Holdings, Inc.'>GDI</a>) trades at $20.78 after pricing its IPO at $20 per share (lower than the original range of $23 to $26).</li> <li>Seeking Alpha contributor Don Dion <a href=\"https://seekingalpha.com/article/4071151-kkr-sponsored-gardner-denver-holdings-set-ipo\" target=\"_blank\">posted</a> analysis earlier this week on the company's return to the public markets.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3262787-gardner-denver-sets-terms-ipo\" target=\"_blank\">Gardner Denver sets terms for IPO</a> (May 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3266754-gardner-denver-prices-ipo-20-share\" target=\"_blank\">Gardner Denver prices IPO at $20/share</a> (May 11)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3266978\" data-linked=\"Gardner Denver +4% in IPO open\" data-tweet=\"$GDI - Gardner Denver +4% in IPO open https://seekingalpha.com/news/3266978-gardner-denverplus-4-in-ipo-open?source=tweet\" data-url=\"https://seekingalpha.com/news/3266978-gardner-denverplus-4-in-ipo-open\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266973\" data-ts=\"1494602109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266973-ardelyx-cant-hold-positive-data-stoked-up-move-shares-slump-32-on-higher-diarrhea-rate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ardelyx can&#39;t hold positive data-stoked up move, shares slump 32% on higher diarrhea rate compared to Linzess</a></h4><ul><li>The hoped-for party at Ardelyx (<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='red'>-32.4%</font>) after it reported positive late-stage results for IBC-C candidate tenapanor has crashed and burned. Shares are down on more than a 12x surge in volume in apparent response to the 14.6% diarrhea rate.</li><li>Investors' reaction is a bit unclear considering the 20% rate for Allergan and Ironwood's&nbsp;<a href=\"https://www.linzess.com/\" target=\"_blank\">Linzess</a>&nbsp;(linaclotide). The diarrhea rate for Synergy Pharmaceuticals' <a href=\"https://www.trulancehcp.com/?gclid=CIjKmOTR6tMCFVaewAodBP0DGg\" target=\"_blank\">Trulance </a>(plecanatide) is 5% in CIC patients (IBS-C indication being investigated).</li></ul><div class=\"tiny-share-widget\" data-id=\"3266973\" data-linked=\"Ardelyx can&#39;t hold positive data-stoked up move, shares slump 32% on higher diarrhea rate compared to Linzess\" data-tweet=\"$ARDX - Ardelyx can&#39;t hold positive data-stoked up move, shares slump 32% on higher diarrhea rate compared to Linzess https://seekingalpha.com/news/3266973-ardelyx-cant-hold-positive-data-stoked-up-move-shares-slump-32-on-higher-diarrhea-rate?source=tweet\" data-url=\"https://seekingalpha.com/news/3266973-ardelyx-cant-hold-positive-data-stoked-up-move-shares-slump-32-on-higher-diarrhea-rate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266976\" data-ts=\"1494601971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266976-twilio-up-ceo-director-buy-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio up as CEO, director buy shares</a></h4><ul>   <li>Twilio (<a href=\"http://seekingalpha.com/symbol/TWLO\" target=\"_blank\">TWLO</a> <font color='green'>+2.4%</font>) SEC filings showed insider buys from leadership this week.</li>    <li>CEO Jeff Lawson <a href=\"https://seekingalpha.com/filing/3546466\" target=\"_blank\">bought 100,000 shares</a> at a price of $23.4318 on Wednesday ($2.34M in total).</li>    <li>Then yesterday, director James McGeever <a href=\"https://seekingalpha.com/filing/3546478\" target=\"_blank\">acquired 10,000 shares</a> at $23.192 each.</li>    <li>Shares had <font color='red'>slid 30%</font> May 3 after posting a <a href=\"https://seekingalpha.com/news/3262530-twilio-tanks-minus-30-percent-despite-q1-beat-outlook-disappoints\" target=\"_blank\">disappointing outlook</a> with Q1 earnings, and have <font color='red'>fallen another 4.8%</font> since.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266976\" data-linked=\"Twilio up as CEO, director buy shares\" data-tweet=\"$TWLO - Twilio up as CEO, director buy shares https://seekingalpha.com/news/3266976-twilio-up-ceo-director-buy-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3266976-twilio-up-ceo-director-buy-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266975\" data-ts=\"1494601714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMCBF\" target=\"_blank\">HMCBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266975-canada-housing-bubble-inflates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canada housing bubble inflates further</a></h4><ul><li>The Teranet-National Bank Composite House Price Index - which measures repeat sales of single-family homes -<a href=\"http://business.financialpost.com/personal-finance/mortgages-real-estate/canadas-home-prices-rise-for-15th-month-straight-on-hefty-gains-in-toronto-hamilton\" target=\"_blank\"> rose another 1.2% in April</a>, including a whopping 2.6% in Toronto.</li><li>With April's gain, home prices in Toronto are now up 26.3% Y/Y; in nearby Hamilton, they're higher by 22.9%.</li><li>In Vancouver, where the local government has taken steps to cool things, prices were lower by 0.1%.</li><li>Meanwhile, mortgage lender Home Capital Group (<a href='https://seekingalpha.com/symbol/HMCBF' title='Home Capital Group Inc.'>OTCPK:HMCBF</a>) is&nbsp;<font color='red'>down more than 10%</font>&nbsp;as it <a href=\"https://seekingalpha.com/news/3266861-home-capital-group-looking-funding\" target=\"_blank\">warns on funding</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266975\" data-linked=\"Canada housing bubble inflates further\" data-tweet=\"$HMCBF - Canada housing bubble inflates further https://seekingalpha.com/news/3266975-canada-housing-bubble-inflates?source=tweet\" data-url=\"https://seekingalpha.com/news/3266975-canada-housing-bubble-inflates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266958\" data-ts=\"1494601479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266958-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PDEX' title='Pro-Dex, Inc.'>PDEX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-60%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-23%</font>. APRI <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266958\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$DRRX $PDEX $SGMO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3266958-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3266958-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266965\" data-ts=\"1494600097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266965-astrazeneca-up-8-on-positive-late-stage-results-for-pd-l1-inhibitor-durvalumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca up 8% on positive late-stage results for PD-L1 inhibitor durvalumab</a></h4><ul><li>AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+7.5%</font>) is enjoying its best up move in at least a year stoked by <a href=\"https://seekingalpha.com/filing/3547284\" target=\"_blank\">positive results</a> from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02125461?term=durvalumab&amp;phase=2&amp;rank=7\" target=\"_blank\">PACIFIC </a>study assessing PD-L1 inhibitor durvalumab, branded as Imfinzi, for the treatment of patients with locally advanced, unresectable non-small cell lung cancer &#40;NSCLC&#41; who had not progressed following platinum-based chemo concurrent with radiation therapy.</li><li>An interim analysis by the Independent Data Monitoring Committee determined that the trial met one of its co-primary endpoints, a statistically valid increase in progression-free survival &#40;PFS&#41; compared to placebo (the other is overall survival which is still being evaluated). Marketing applications will be submitted as soon as feasible.</li><li>The FDA recently granted accelerated approval of durvalumab for advanced bladder cancer. Phase 3 studies are in process for first-line NSCLC (monotherapy) and in combination with tremelimumab.</li><li>The company expects durvalumab to be one of its growth drivers although Merck's Keytruda (pembrolizumab) will represent a significant headwind.</li><li>Recent coverage updates: Barclays and Liberum Capital (Buy), Jefferies and JPMorgan (Neutral) and Goldman and Shore Capital (Sell).</li></ul><div class=\"tiny-share-widget\" data-id=\"3266965\" data-linked=\"AstraZeneca up 8% on positive late-stage results for PD-L1 inhibitor durvalumab\" data-tweet=\"$AZN - AstraZeneca up 8% on positive late-stage results for PD-L1 inhibitor durvalumab https://seekingalpha.com/news/3266965-astrazeneca-up-8-on-positive-late-stage-results-for-pd-l1-inhibitor-durvalumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3266965-astrazeneca-up-8-on-positive-late-stage-results-for-pd-l1-inhibitor-durvalumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266964\" data-ts=\"1494598756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CM\" target=\"_blank\">CM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266964-privatebancorp-owners-approve-cibc-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PrivateBancorp owners approve CIBC bid</a></h4><ul><li>To review, the terms of CIBC's (<a href='https://seekingalpha.com/symbol/CM' title='Canadian Imperial Bank of Commerce'>CM</a> flat) revised cash and stock offer (on March 30) valued PrivateBancorp (<a href='https://seekingalpha.com/symbol/PVTB' title='PrivateBancorp, Inc.'>PVTB</a> <font color='green'>+0.4%</font>) at $4.9B, or $60.92 per share at that time.</li><li>PVTB is currently is trading hands at $59.73.</li><li>The sale is <a href=\"https://seekingalpha.com/pr/16831649-privatebancorp-stockholders-approve-acquisition-cibc\" target=\"_blank\">hoped to close</a> in June.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266964\" data-linked=\"PrivateBancorp owners approve CIBC bid\" data-tweet=\"$CM $CM $PVTB - PrivateBancorp owners approve CIBC bid https://seekingalpha.com/news/3266964-privatebancorp-owners-approve-cibc-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3266964-privatebancorp-owners-approve-cibc-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266962\" data-ts=\"1494597970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DKS\" target=\"_blank\">DKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266962-dicks-sporting-goodsminus-6-after-disclosing-accounting-error\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dick&#39;s Sporting Goods -6% after disclosing accounting error</a></h4><ul> <li>Dick's Sporting Goods (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color='red'>-6.4%</font>) falls hard after the company discloses that it overstated Q4 and FY17 EBITDA by $23.4M.</li> <li>The retailer says a \"computational error\" led to the misreported numbers.</li> <li><a href=\"https://seekingalpha.com/filing/3547375\" target=\"_blank\">SEC Form 8-K</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3266962\" data-linked=\"Dick&#39;s Sporting Goods -6% after disclosing accounting error\" data-tweet=\"$DKS - Dick&#39;s Sporting Goods -6% after disclosing accounting error https://seekingalpha.com/news/3266962-dicks-sporting-goodsminus-6-after-disclosing-accounting-error?source=tweet\" data-url=\"https://seekingalpha.com/news/3266962-dicks-sporting-goodsminus-6-after-disclosing-accounting-error\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266959\" data-ts=\"1494597749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXTR\" target=\"_blank\">DXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266959-dextera-prices-equity-offering-shares-down-42\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dextera prices equity offering; shares down 42%</a></h4><ul><li>Thinly traded nano cap Dextera Surgical (<a href='https://seekingalpha.com/symbol/DXTR' title='Dextera Surgical Inc.'>OTC:DXTR</a> <font color='red'>-41.8%</font>) slumps on a 4x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16831599-dextera-surgical-announces-8-million-underwritten-public-offering\" target=\"_blank\">public offering</a> of 8,000 shares of Series B convertible preferred stock and related warrants at $1,000 per share.</li><li>Each Series B share, convertible into 3,704 common shares at $0.27, will have 3,704 five-year series 1 warrants to purchase common shares at $0.27 and 1,852 one-year series 2 warrants to purchase common shares at $0.27.</li><li>In total, the Series B stock is convertible into 29.6M shares of common stock and the warrants are exercisable for 44.5M shares of common.</li><li>Net proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266959\" data-linked=\"Dextera prices equity offering; shares down 42%\" data-tweet=\"$DXTR - Dextera prices equity offering; shares down 42% https://seekingalpha.com/news/3266959-dextera-prices-equity-offering-shares-down-42?source=tweet\" data-url=\"https://seekingalpha.com/news/3266959-dextera-prices-equity-offering-shares-down-42\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266957\" data-ts=\"1494597636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTR\" target=\"_blank\">FTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266957-frontier-communications-sets-reverse-split-1-forminus-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontier Communications sets reverse split at 1-for-15</a></h4><ul>   <li>Following shareholder approval on Wednesday, Frontier Communications (<a href=\"http://seekingalpha.com/symbol/FTR\" target=\"_blank\">FTR</a> <font color='green'>+2.1%</font>) has set its <a href=\"https://seekingalpha.com/pr/16831422-frontier-communications-board-sets-reverse-stock-split-ratio-effective-date\" target=\"_blank\">reverse split ratio at 1-for-15</a>.</li>    <li>That ratio will be effective with the start of trading July 10.</li>    <li>Authorized shares will go from 1.75B to 175M.</li>    <li>The stock has fallen to $1.23, <font color='red'>down 63.6%</font> YTD and <font color='red'>down 76.9%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266957\" data-linked=\"Frontier Communications sets reverse split at 1-for-15\" data-tweet=\"$FTR - Frontier Communications sets reverse split at 1-for-15 https://seekingalpha.com/news/3266957-frontier-communications-sets-reverse-split-1-forminus-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3266957-frontier-communications-sets-reverse-split-1-forminus-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266955\" data-ts=\"1494597584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWR\" target=\"_blank\">WWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266955-uranium-resources-up-nearly-10-after-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uranium Resources up nearly 10% after results</a></h4><ul><li>Q1 income of $1.845M or $0.09 per share vs. a loss of $4.27M and $0.86 one year ago. Working capital of $11.4M at quarter's end.</li><li>Net cash used in operations of $3.3M vs. $2.2M.</li><li>G&amp;A expense of $1.7M down 22% from $2.1M.</li><li>Float of 21.6M shares up from 5M.</li><li>Current cash is expected to fund critical operations into Q1 of 2018. Additional capital raises are to be expected, which could include the sale of additional non-core assets.</li><li>URRE<font color='green'> +9.3%</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3266769-uranium-resources-reports-q1-results\" target=\"_blank\">Uranium Resources reports Q1 results</a> (May 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3266955\" data-linked=\"Uranium Resources up nearly 10% after results\" data-tweet=\"$WWR - Uranium Resources up nearly 10% after results https://seekingalpha.com/news/3266955-uranium-resources-up-nearly-10-after-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3266955-uranium-resources-up-nearly-10-after-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266948\" data-ts=\"1494596734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266948-celsion-q1-operating-loss-4_8m-shares-up-15-on-potential-thermodox-marketing-application-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion Q1 operating loss $4.8M; shares up 15% on potential ThermoDox marketing application in China if OPTIMA study successful</a></h4><ul><li>Penny stock Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+15.3%</font>) jumps on modestly higher volume after the company <a href=\"https://seekingalpha.com/pr/16831450-celsion-corporation-reports-first-quarter-2017-financial-results-provides-business-update\" target=\"_blank\">reported </a>Q1 results that included an update on lead product candidate ThermoDox.</li><li>The company said it met with the China Food and Drug Administration &#40;CFDA&#41; to review the ongoing Phase 3 OPTIMA liver cancer study and a regulatory pathway for ThermoDox. CFDA officials informed the company that if OPTIMA is successful, the data could serve as the basis for a marketing application there without prior approval in the U.S. or EU, the current norm for a foreign applicant.</li><li>The company reported an operating loss of $4.8M in Q1 and a cash balance of ~$4.5M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266948\" data-linked=\"Celsion Q1 operating loss $4.8M; shares up 15% on potential ThermoDox marketing application in China if OPTIMA study successful\" data-tweet=\"$CLSN - Celsion Q1 operating loss $4.8M; shares up 15% on potential ThermoDox marketing application in China if OPTIMA study successful https://seekingalpha.com/news/3266948-celsion-q1-operating-loss-4_8m-shares-up-15-on-potential-thermodox-marketing-application-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3266948-celsion-q1-operating-loss-4_8m-shares-up-15-on-potential-thermodox-marketing-application-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266943\" data-ts=\"1494595887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266943-ziopharm-prices-equity-offering-shares-down-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZIOPHARM prices equity offering; shares down 11%</a></h4><ul><li>ZIOPHARM Oncology (<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color='red'>-11.2%</font>) <a href=\"https://seekingalpha.com/pr/16831604-ziopharm-oncology-announces-pricing-50-million-follow-offering-common-stock\" target=\"_blank\">prices </a>its direct offering of 9,708,738 common shares at $5.15 to a single institutional investor. Net proceeds will fund working capital and general corporate purposes. Closing date is May 16.</li><li>Yesterday's close was $7.12.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266943\" data-linked=\"ZIOPHARM prices equity offering; shares down 11%\" data-tweet=\"$ZIOP - ZIOPHARM prices equity offering; shares down 11% https://seekingalpha.com/news/3266943-ziopharm-prices-equity-offering-shares-down-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3266943-ziopharm-prices-equity-offering-shares-down-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266942\" data-ts=\"1494595766\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNJN\" target=\"_blank\">FNJN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266942-finjan-holdingsplus-12_6-after-preliminary-q1-revenues-gain-tenfold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finjan Holdings +12.6% after preliminary Q1 revenues gain tenfold</a></h4><ul>   <li>Cybersecurity firm Finjan Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>) is <font color='green'>up 12.6%</font> premarket after saying it's pulled off a record first quarter with revenues <a href=\"https://seekingalpha.com/pr/16831073-finjan-provides-shareholder-update-record-first-quarter-2017\" target=\"_blank\">up by a factor of 10</a>.</li>    <li>Revenues of $24.7M compared to just $2.3M a year ago, and the company posted net income from operations of $16M ($0.69/share).</li>    <li>The company used revenues to retire all of its Series A financing: $7.2M in Series A preferred stock by quarter's end, and then $6.6M in a remaining balance after March 31.</li>    <li>It wrapped the quarter with $26.4M in cash, about $1.14/share.</li>    <li>The company plans a <a href=\"https://seekingalpha.com/pr/16822231-finjan-holdings-host-1q-shareholder-update-call-may-15-2017\" target=\"_blank\">shareholder update call</a> for Monday at 4:30 p.m. ET.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266942\" data-linked=\"Finjan Holdings +12.6% after preliminary Q1 revenues gain tenfold\" data-tweet=\"$FNJN - Finjan Holdings +12.6% after preliminary Q1 revenues gain tenfold https://seekingalpha.com/news/3266942-finjan-holdingsplus-12_6-after-preliminary-q1-revenues-gain-tenfold?source=tweet\" data-url=\"https://seekingalpha.com/news/3266942-finjan-holdingsplus-12_6-after-preliminary-q1-revenues-gain-tenfold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266939\" data-ts=\"1494595506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/W\" target=\"_blank\">W</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266939-wayfair-stumbles-on-amazon-furniture-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wayfair stumbles on Amazon furniture news</a></h4><ul> <li>Wayfair (NYSE:<a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a>) investors appear to be reacting to today's news of a deeper commitment by Amazon into furniture.</li> <li>Shares of Wayfair are <font color='red'>down 6.41%</font> premarket to $60.40. It's only a minor stumble for a stock already up 84% YTD.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3266932-amazon-thinks-big-new-delivery-push\" target=\"_blank\">Amazon thinks big with new delivery push</a> (May 12)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3266939\" data-linked=\"Wayfair stumbles on Amazon furniture news\" data-tweet=\"$W - Wayfair stumbles on Amazon furniture news https://seekingalpha.com/news/3266939-wayfair-stumbles-on-amazon-furniture-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3266939-wayfair-stumbles-on-amazon-furniture-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266938\" data-ts=\"1494595427\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266938-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+41%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3266695\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a> <font color='green'>+21%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3266614-trade-desk-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+18%</font>&nbsp;on deal with EPA.</li><li><a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+16%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3266696-finjan-holdings-reports-q1-results\" target=\"_blank\">result</a>.</li><li>URRE <font color='green'>+11%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3266769-uranium-resources-reports-q1-results\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+7%</font>&nbsp;on &nbsp;Imfinzi <a href=\"https://seekingalpha.com/news/3266792-astrazeneca-rises-imfinzi-results\" target=\"_blank\">results</a>.</li><li><a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='green'>+5%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3266889-petrobras-petroleo-brasileiro-s-reports-q1-results\" target=\"_blank\">result</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266938\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$TCCO $TTD $NAK - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3266938-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3266938-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266936\" data-ts=\"1494595227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOGO\" target=\"_blank\">FOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266936-fogo-de-chao-prices-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fogo de Cho prices secondary offering</a></h4><ul> <li>Fogo de Ch&atilde;o (NASDAQ:<a href='https://seekingalpha.com/symbol/FOGO' title='Fogo de Chao'>FOGO</a>) prices a secondary offering of 4.5M shares at $14 per share.</li><li>The stake is being sold by certain funds affiliated with Thomas H. Lee Partners.The company will not receive any proceeds from the offering.</li><li>The offering is expected to close on May 17.</li>  <li>FOGO  <font color='red'>-3.02%</font> premarket to  $14.45.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16831236-fogo-de-chao-inc-announces-pricing-secondary-offering-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3266936\" data-linked=\"Fogo de Cho prices secondary offering\" data-tweet=\"$FOGO - Fogo de Cho prices secondary offering https://seekingalpha.com/news/3266936-fogo-de-chao-prices-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3266936-fogo-de-chao-prices-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266934\" data-ts=\"1494594914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266934-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a>&nbsp;<font color='red'>-37%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3266855-ardelyxs-tenapanor-successful-late-stage-ibs-c-study-shares-ahead-2-percent-premarket\" target=\"_blank\">announcing</a> positive results in a Phase 3 clinical trial, T3MPO-1.</li><li><a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3266896-akari-places-ceo-administrative-leave-board-investigates-research-report-coversin-shares-18\" target=\"_blank\">placing</a> its CEO Dr. Gur Roshwalk on administrative leave.</li><li><a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3266641-chromadex-misses-0_06-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a>&nbsp;<font color='red'>-8%</font>&nbsp;on below consensus <a href=\"https://seekingalpha.com/news/3266756-cyberark-minus-6_4-percent-q1-features-downbeat-profit-guidance\" target=\"_blank\">guidance</a>.</li><li><a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a><font color='red'>-6%</font>&nbsp;on disappointing <a href=\"https://seekingalpha.com/news/3266865-j-c-penney-slumps-sales-disappoint\" target=\"_blank\">sales results</a>.</li><li><a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>&nbsp;<font color='red'>-5%</font>&nbsp;on missing <a href=\"https://seekingalpha.com/news/3266672-nordstrom-lower-earnings\" target=\"_blank\">comparable sales</a> estimates.</li><li><a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3266881-arcelormittal-beats-0_06-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3266934\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ARDX $AKTX $CDXC - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3266934-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3266934-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266933\" data-ts=\"1494594874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266933-treasurys-rally-after-soft-retail-sales-inflation-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasurys rally after soft retail sales, inflation numbers</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3266894-retail-sales-expectations-april\" target=\"_blank\">Retail sales rose</a> again in April, but came in shy of forecasts - control group +0.2% vs. +0.4% expected, and +0.7% prior.</li><li><a href=\"https://seekingalpha.com/news/3266892-cpi-rises-line-forecasts\" target=\"_blank\">Core CPI rose just 0.1%</a> for the month vs. 0.2% expected. On a year-over-year basis, core CPI was higher by 1.9%, the slowest since October 2015.</li><li>Treasury yields have been on the move higher for the past couple of weeks, but they're lower following this news - the 10-year down 4.6 basis points to 2.344%.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.4%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-0.8%</font></li><li>The dollar is also lower, with <a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a>&nbsp;<font color='red'>-0.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266933\" data-linked=\"Treasurys rally after soft retail sales, inflation numbers\" data-tweet=\"$TLT $TBT $UUP - Treasurys rally after soft retail sales, inflation numbers https://seekingalpha.com/news/3266933-treasurys-rally-after-soft-retail-sales-inflation-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3266933-treasurys-rally-after-soft-retail-sales-inflation-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266930\" data-ts=\"1494594798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLW\" target=\"_blank\">GLW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266930-corningplus-1_9-on-200m-investment-from-apple-jobs-fund\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corning +1.9% on $200M investment from Apple jobs fund</a></h4><ul>   <li>Corning (NYSE:<a href='https://seekingalpha.com/symbol/GLW' title='Corning Inc.'>GLW</a>) is <font color='green'>up 1.9%</font> premarket on word it's the <a href=\"http://www.foxbusiness.com/markets/2017/05/12/apple-picks-corning-kentucky-for-manufacturing-investment.html\" target=\"_blank\">first recipient of funding</a> -- $200M -- from a $1B fund from Apple established to <a href=\"https://seekingalpha.com/news/3263257-apple-invest-1b-fund-create-u-s-manufacturing-jobs\" target=\"_blank\">promote advanced manufacturing in the U.S.</a></li>    <li>Apple had said last week that an announcement was coming soon on which firm would be drawing from that fund first.</li>    <li>The money goes to the Harrodsburg, Kentucky plant of the maker of break-resistant Gorilla Glass.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266930\" data-linked=\"Corning +1.9% on $200M investment from Apple jobs fund\" data-tweet=\"$GLW - Corning +1.9% on $200M investment from Apple jobs fund https://seekingalpha.com/news/3266930-corningplus-1_9-on-200m-investment-from-apple-jobs-fund?source=tweet\" data-url=\"https://seekingalpha.com/news/3266930-corningplus-1_9-on-200m-investment-from-apple-jobs-fund\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266925\" data-ts=\"1494594324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTK\" target=\"_blank\">CYTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266925-cytokinetics-ckminus-2127107-orphan-drug-for-sma-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cytokinetics&#39; CK-2127107 an Orphan Drug for SMA; shares ahead 4% premarket</a></h4><ul><li>Cytokinetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a>) perks up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume in apparent response to the FDA <a href=\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=516215\" target=\"_blank\">designating</a> CK-2127107, a next-generation fast skeletal troponin activator, an Orphan Drug for the treatment of spinal muscular atrophy &#40;SMA&#41;.</li><li>A 72-subject <a href=\"https://clinicaltrials.gov/ct2/show/NCT02644668?term=ck-2127107&amp;rank=3\" target=\"_blank\">Phase 2 clinical trial </a>started about two month ago.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266925\" data-linked=\"Cytokinetics&#39; CK-2127107 an Orphan Drug for SMA; shares ahead 4% premarket\" data-tweet=\"$CYTK - Cytokinetics&#39; CK-2127107 an Orphan Drug for SMA; shares ahead 4% premarket https://seekingalpha.com/news/3266925-cytokinetics-ckminus-2127107-orphan-drug-for-sma-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3266925-cytokinetics-ckminus-2127107-orphan-drug-for-sma-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266914\" data-ts=\"1494593555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266914-loxos-larotrectinib-orphan-drug-for-certain-type-of-solid-tumors-shares-ahead-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loxo&#39;s larotrectinib an Orphan Drug for certain type of solid tumors; shares ahead 3% premarket</a></h4><ul><li>Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;premarket, albeit on only 150 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16831356-loxo-oncology-announces-fda-orphan-drug-designation-granted-larotrectinib-treatment-solid\" target=\"_blank\">announcement </a>that the FDA has designated larotrectinib (LOXO-101) an Orphan Drug for the treatment of solid tumors with rare genetic abnormalities called NTRK-fusion proteins.</li><li><a href=\"https://www.loxooncology.com/pipeline#loxo-101\" target=\"_blank\">LOXO-101</a>&nbsp;inhibits a group of enzymes called tropomyosin receptor kinases &#40;TRK&#41;, a group of proteins that plays a key role in cellular communications. Cancers hijack these communication pathways to send messages to the cells to grow, change or survive. Those characterized by these alterations, termed NTRK fusions, are the therapeutic targets for LOXO-101.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266914\" data-linked=\"Loxo&#39;s larotrectinib an Orphan Drug for certain type of solid tumors; shares ahead 3% premarket\" data-tweet=\"$LOXO - Loxo&#39;s larotrectinib an Orphan Drug for certain type of solid tumors; shares ahead 3% premarket https://seekingalpha.com/news/3266914-loxos-larotrectinib-orphan-drug-for-certain-type-of-solid-tumors-shares-ahead-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3266914-loxos-larotrectinib-orphan-drug-for-certain-type-of-solid-tumors-shares-ahead-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266912\" data-ts=\"1494593542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266912-barclays-pushes-in-on-wynn-resorts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays pushes in on Wynn Resorts</a></h4><ul> <li>Barclays <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Barclays+Upgrades+Wynn+Resorts+%28WYNN%29+to+Overweight%2C+%22Jumping+Back+On+The+Macau+Train%22/12895381.html\" target=\"_blank\">upgrades</a> Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) to an Overweight rating after having the casino stock lined up at Equalweight. Analyst Felicia Hendrizx cites the various tailwinds blowing in from Macau and Las Vegas.</li> <li>The investment firm takes its price target all the way up to $144.00 to rep 18% upside potential for shares. The $144 PT is based off of an estimate for 2017 EPS of $5.66 (25.44 PE) and 2018 EPS of $6.14 (23.45 PE). The PT is also well-past the 52-week high on Wynn of $127.20.</li>  <li>WYNN <font color='green'>+1.41%</font> premarket to $123.95.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266912\" data-linked=\"Barclays pushes in on Wynn Resorts\" data-tweet=\"$WYNN - Barclays pushes in on Wynn Resorts https://seekingalpha.com/news/3266912-barclays-pushes-in-on-wynn-resorts?source=tweet\" data-url=\"https://seekingalpha.com/news/3266912-barclays-pushes-in-on-wynn-resorts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266896\" data-ts=\"1494592407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266896-akari-places-ceo-on-administrative-leave-while-board-investigates-research-report-on-coversin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari places CEO on administrative leave while board investigates research report on Coversin; shares down 18% premarket</a></h4><ul><li>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a>) slumps&nbsp;<font color='red'>18%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/filing/3546188\" target=\"_blank\">announcement&nbsp;</a>that it has placed CEO Dr. Gur Roshwalk on administrative leave while a special committee of the board investigates the potential involvement of company employees with a report published last month by Edison Investment Research which showed lead product candidate Coversin was non-inferior to Alexion's Soliris (eculizumab) in a mid-stage paroxysmal nocturnal hemoglobinuria &#40;PNH&#41; study.</li><li>In a <a href=\"https://seekingalpha.com/pr/16831337-edison-investment-research-issues-statement-akari-therapeutics-statements-sec-filing-citing\" target=\"_blank\">statement</a> issued today, Edison says the company signed off on the report as written and, an in-depth investigation notwithstanding, Akari has yet to provide evidence of any alleged inaccuracies despite multiple requests from Edison and its legal counsel.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266896\" data-linked=\"Akari places CEO on administrative leave while board investigates research report on Coversin; shares down 18% premarket\" data-tweet=\"$AKTX - Akari places CEO on administrative leave while board investigates research report on Coversin; shares down 18% premarket https://seekingalpha.com/news/3266896-akari-places-ceo-on-administrative-leave-while-board-investigates-research-report-on-coversin?source=tweet\" data-url=\"https://seekingalpha.com/news/3266896-akari-places-ceo-on-administrative-leave-while-board-investigates-research-report-on-coversin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266889\" data-ts=\"1494592155\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266889-petrobras-petroleo-brasileiro-s-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras - Petroleo Brasileiro S.A. reports Q1 results</a></h4><ul><li>Petrobras - Petroleo Brasileiro S.A. (NYSE:<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a>): Q1 EPS of $0.11</li><li>Revenue of $21.74B (+20.8% Y/Y)</li><li>Shares <font color='green'>+4.12%</font> PM.</li><li><a href='http://www.investidorpetrobras.com.br/en/financial-results/holding'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3266889\" data-linked=\"Petrobras - Petroleo Brasileiro S.A. reports Q1 results\" data-tweet=\"$PBR - Petrobras - Petroleo Brasileiro S.A. reports Q1 results https://seekingalpha.com/news/3266889-petrobras-petroleo-brasileiro-s-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3266889-petrobras-petroleo-brasileiro-s-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266867\" data-ts=\"1494589636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAK\" target=\"_blank\">NAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266867-northern-dynasty-and-epa-come-to-terms-shares-up-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northern Dynasty and EPA come to terms; shares up 15% premarket</a></h4><ul><li><a href=\"http://www.northerndynastyminerals.com/ndm/NewsReleases.asp?ReportID=789760\" target=\"_blank\">Under terms of the deal</a>, Northern Dynasty's (NYSEMKT:<a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a>) Pebble Project can proceed into normal permitting under the Clean Water Act - in particular, EPA has agreed not to file a Recommended Determination under CWA.</li><li>NAK CEO Ron Thiessen: \"From the outset of this unfortunate saga, we've asked for nothing more than fairness and due process under the law ... Today's settlement gives us precisely that, the same treatment every developer and investor in a stable, first world country should expect.\"</li><li>Shares&nbsp;<font color='green'>+15.2%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3266867\" data-linked=\"Northern Dynasty and EPA come to terms; shares up 15% premarket\" data-tweet=\"$NAK - Northern Dynasty and EPA come to terms; shares up 15% premarket https://seekingalpha.com/news/3266867-northern-dynasty-and-epa-come-to-terms-shares-up-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3266867-northern-dynasty-and-epa-come-to-terms-shares-up-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266865\" data-ts=\"1494589559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266865-j-c-penney-slumps-after-sales-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney slumps after sales disappoint</a></h4><ul> <li>J.C. Penney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>) reports comparable sales fell 3.5% in Q1 to miss the consensus estimate for a 0.7% drop. Strength was cited by management for the Home, Sephora, Fine Jewelry and Salon businesses.</li> <li>Gross margin was reported at 36.3% of sales vs. 36.2% a year ago and 36.1% consensus. SG&amp;A expenses were 31.2% of sales.</li> <li>\"While February was a very challenging month for JCPenney and broader retail, we are pleased with our comp store sales for the combined March and April period, which improved significantly versus February,\" says CEO Marvin Ellison.</li> <li>Looking ahead, J.C. Penney expects comparable sales growth to be -1% to +1% for the full year and EPS to land in range of $0.40 to $0.65.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3266859-j-c-penney-beats-0_27-misses-revenue\" target=\"_blank\">J.C. Penney beats by $0.27, misses on revenue</a> (May 12)</li> <li>JCP <font color='red'>-7.37%</font> premarket to $4.90 (52-week low)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3266865\" data-linked=\"J.C. Penney slumps after sales disappoint\" data-tweet=\"$JCP - J.C. Penney slumps after sales disappoint https://seekingalpha.com/news/3266865-j-c-penney-slumps-after-sales-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3266865-j-c-penney-slumps-after-sales-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266864\" data-ts=\"1494589440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266864-lillys-galcanezumab-successful-in-three-late-stage-migraine-studies-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly&#39;s galcanezumab successful in three late-stage migraine studies; shares ahead 2% premarket</a></h4><ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16831354-lilly-announces-positive-results-three-phase-3-studies-galcanezumab-prevention-episodic\" target=\"_blank\">announcement </a>of positive results from three Phase 3 clinical trials assessing galcanezumab for the prevention of episodic and chronic migraine. All three studies, EVOLVE-1, EVOLVE-2 and REGAIN, met their primary endpoints of showing statistically valid reductions in the number of monthly migraine days compared to placebo at both studied doses.</li><li>The company plans to file its Biologics Licence Application &#40;BLA&#41; with the FDA in H2. Regulatory submissions in ex-U.S. markets will follow.</li><li>Galcanezumab is a monoclonal antibody that binds to a compound produced in neurons called <a href=\"https://en.wikipedia.org/wiki/Calcitonin_gene-related_peptide\" target=\"_blank\">calcitonin gene-related peptide</a> &#40;CGRP&#41; that plays a key role in the transmission of pain. It is administered once per month via subcutaneous injection.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266864\" data-linked=\"Lilly&#39;s galcanezumab successful in three late-stage migraine studies; shares ahead 2% premarket\" data-tweet=\"$LLY - Lilly&#39;s galcanezumab successful in three late-stage migraine studies; shares ahead 2% premarket https://seekingalpha.com/news/3266864-lillys-galcanezumab-successful-in-three-late-stage-migraine-studies-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3266864-lillys-galcanezumab-successful-in-three-late-stage-migraine-studies-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266863\" data-ts=\"1494589245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266863-deutsche-bank-lowers-ge-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank lowers GE to Sell</a></h4><ul><li>General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) <font color='red'>-1.6%</font> premarket after Deutsche Bank downgraded shares to Sell from Hold and reduced their price target  to $24 (from $28).</li><li>According to the firm: The stock is overvalued given \"weak earnings quality\" and the \"wide gap between non-cash and cash earnings.\"</li><li>GE's cash flow has become worse in recent quarters and that the exclusion of non-operating pension accounting along with a high level of underfunded pension obligations create earnings quality pressures.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266863\" data-linked=\"Deutsche Bank lowers GE to Sell\" data-tweet=\"$GE - Deutsche Bank lowers GE to Sell https://seekingalpha.com/news/3266863-deutsche-bank-lowers-ge-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3266863-deutsche-bank-lowers-ge-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>97&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266859\" data-ts=\"1494588938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266859-j-c-penney-beats-0_27-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney beats by $0.27, misses on revenue</a></h4><ul><li>J.C. Penney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>): Q1 EPS of $0.06 <font color='green'>beats by $0.27</font>.</li><li>Revenue of $2.71B (-3.6% Y/Y) <font color='red'>misses by $60M</font>.</li><li>Shares <font color='green'>+1.32%</font> PM.</li><li><a href='http://ir.jcpenney.com/phoenix.zhtml?c=70528&p=irol-newsCompanyArticle&ID=2272604'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3266859\" data-linked=\"J.C. Penney beats by $0.27, misses on revenue\" data-tweet=\"$JCP - J.C. Penney beats by $0.27, misses on revenue https://seekingalpha.com/news/3266859-j-c-penney-beats-0_27-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3266859-j-c-penney-beats-0_27-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266855\" data-ts=\"1494588568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266855-ardelyxs-tenapanor-successful-in-late-stage-ibs-c-study-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ardelyx&#39;s tenapanor successful in late-stage IBS-C study; shares ahead 2% premarket</a></h4><ul><li>Thinly traded micro cap Ardelyx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a>) perks up&nbsp;<font color='green'>2%&nbsp;</font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16831350-ardelyx-reports-successful-phase-3-t3mpominus-1-trial-tenapanor-patients-ibs-c\" target=\"_blank\">announcement </a>of positive results in a Phase 3 clinical trial, T3MPO-1, assessing lead product candidate tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C).</li><li>The study met its primary endpoint of overall responder rate for six of 12 weeks. Specifically, 27.0% of the treatment group experienced at least a 30% reduction in abdominal pain and an increase of one or more spontaneous bowel movements in the same week for at least half of the 12 weeks of the treatment period compared to 18.7% for placebo (p=0.02).</li><li>The safety profile of tenapanor was consistent with previous studies. The most common adverse event was diarrhea (14.6%).</li><li>Data from a second Phase 3, T3MPO-2, are expected in Q4. Patients who have completed either study will be eligible to enroll in an open-label, long-term safety trial called T3MPO-3 under which they can continue to receive tenapanor for up to one year.</li><li>Tenapanor inhibits the intestinal sodium transporter&nbsp;<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19448074\" target=\"_blank\">NHE3</a>. It has demonstrated the ability to reduce the absorption of dietary sodium and phosphate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266855\" data-linked=\"Ardelyx&#39;s tenapanor successful in late-stage IBS-C study; shares ahead 2% premarket\" data-tweet=\"$ARDX - Ardelyx&#39;s tenapanor successful in late-stage IBS-C study; shares ahead 2% premarket https://seekingalpha.com/news/3266855-ardelyxs-tenapanor-successful-in-late-stage-ibs-c-study-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3266855-ardelyxs-tenapanor-successful-in-late-stage-ibs-c-study-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266850\" data-ts=\"1494587933\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MT\" target=\"_blank\">MT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266850-arcelormittalminus-4_4-despite-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArcelorMittal -4.4% despite earnings beat</a></h4><ul><li>A recovery in steel prices had Q1 profit at ArcelorMittal (NYSE:<a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a>) more than doubled from a year ago.</li><li>Free cash flow was negative, however, <a href=\"https://www.thestreet.com/story/14132407/1/arcelormittal-and-thyssenkrupp-tumble-despite-strongh-first-quarters.html\" target=\"_blank\">and investors may be disappointed</a> that there was no boost to full-year earnings guidance.</li><li>Fellow steelmaker Thyssenkrupp (<a href='https://seekingalpha.com/symbol/TKAMY' title='ThyssenKrupp AG ADR'>OTCPK:TKAMY</a>, <a href='https://seekingalpha.com/symbol/TYEKF' title='ThyssenKrupp AG'>OTCPK:TYEKF</a>) also reported pleasing results, and boosted full-year earnings guidance. It did, however, cut free cash flow guidance to negative from positive.</li><li>Thyssenkrupp CEO Heinrich Hiesinger: \"The raw materials markets and as a result our materials businesses are subject to large swings that are beyond our control.\"</li><li>MT&nbsp;<font color='red'>-4.4%</font>&nbsp;premarket. Thyssenkrupp<font color='red'> -2.75%</font>&nbsp;in German action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266850\" data-linked=\"ArcelorMittal -4.4% despite earnings beat\" data-tweet=\"$MT $MT $TKAMY - ArcelorMittal -4.4% despite earnings beat https://seekingalpha.com/news/3266850-arcelormittalminus-4_4-despite-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3266850-arcelormittalminus-4_4-despite-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266838\" data-ts=\"1494587362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266838-interim-data-not-good-for-capricors-lead-product-candidate-in-mid-stage-heart-study-focus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interim data not good for Capricor&#39;s lead product candidate in mid-stage heart study, focus shifts to DMD; job cuts planned; shares off 33% premarket</a></h4><ul><li>Thinly traded nano cap Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) plummets&nbsp;<font color='red'>33%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16831345-capricor-therapeutics-provides-update-allstar-trial\" target=\"_blank\">announcement </a>that its Phase 2 clinical trial, ALLSTAR, assessing lead product candidate CAP-1002 for the treatment of adults who have experienced a large heart attack with residual cardiac dysfunction is unlikely to achieve its primary endpoint.</li><li>At six months, the treatment group showed a near-statistically significant reduction of average end-diastolic volume and a trend of reduction of average end-systolic volume, but there was no difference compared to placebo in ejection fraction.</li><li>CEO Linda Marb&aacute;n says,&nbsp;\"The lack of a clear difference in the change in scar size from baseline to six months between the active and control groups in the interim observations from <a href=\"https://clinicaltrials.gov/ct2/show/NCT01458405?term=cap-1002&amp;phase=1&amp;rank=3\" target=\"_blank\">ALLSTAR </a>was unexpected. These results diverge from the consistent and extensive record of activity observed with our cell technology in the setting of cardiac fibrosis as demonstrated by both preclinical and clinical studies, and we hope to gain an understanding of the factors that led to these observations through the conduct of further analyses.\"</li><li>The company plans to focus its CAP-1002 development efforts on Duchenne muscular dystrophy &#40;DMD&#41;. The strategic realignment will require it to reduce the scope of its operations, including the downsizing of its workforce.</li><li><a href=\"http://capricor.com/product-pipeline/cap-1002/\" target=\"_blank\">CAP-1002</a>&nbsp;is an investigational allogeneic, off-the-shelf cardiac cell therapy derived from donor heart tissue and infused directly into the patients coronary artery via a catheter.&nbsp;It is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack).</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the situation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3218663-capricors-lead-product-candidate-shows-mixed-results-early-stage-heart-failure-study-shares-2\" target=\"_blank\">Capricor's lead product candidate shows mixed results in early-stage heart failure study; shares off 2%</a> (Oct. 31, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3266838\" data-linked=\"Interim data not good for Capricor&#39;s lead product candidate in mid-stage heart study, focus shifts to DMD; job cuts planned; shares off 33% premarket\" data-tweet=\"$CAPR - Interim data not good for Capricor&#39;s lead product candidate in mid-stage heart study, focus shifts to DMD; job cuts planned; shares off 33% premarket https://seekingalpha.com/news/3266838-interim-data-not-good-for-capricors-lead-product-candidate-in-mid-stage-heart-study-focus?source=tweet\" data-url=\"https://seekingalpha.com/news/3266838-interim-data-not-good-for-capricors-lead-product-candidate-in-mid-stage-heart-study-focus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266842\" data-ts=\"1494587245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDW\" target=\"_blank\">TDW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266842-tidewater-in-pre-packaged-bankruptcy-deal-sharesminus-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tidewater in pre-packaged bankruptcy deal; shares -20%</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16831353-tidewater-announces-entry-restructuring-support-agreement-certain-lenders-noteholders\" target=\"_blank\">has inked a Restructuring Support Agreement </a>with certain of its lenders, and expects to file for chapter 11 by next Wednesday.</li><li>Tidewater (NYSE:<a href='https://seekingalpha.com/symbol/TDW' title='Tidewater, Inc.'>TDW</a>) continues to negotiate with the NYSE about keeping its listing through the restructuring process.</li><li>Under the deal, existing common stockholders will be wiped out, and receive common stock in the reorganized Tidewater representing 5% of the company, along with two sets of warrants.</li><li>Shares&nbsp;<font color='red'>-19.75%</font>&nbsp;premarket to $0.712.</li></ul><div class=\"tiny-share-widget\" data-id=\"3266842\" data-linked=\"Tidewater in pre-packaged bankruptcy deal; shares -20%\" data-tweet=\"$TDW - Tidewater in pre-packaged bankruptcy deal; shares -20% https://seekingalpha.com/news/3266842-tidewater-in-pre-packaged-bankruptcy-deal-sharesminus-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3266842-tidewater-in-pre-packaged-bankruptcy-deal-sharesminus-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>198&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3266792\" data-ts=\"1494578879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3266792-astrazeneca-rises-on-imfinzi-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca rises on Imfinzi results</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) <font color='green'>+4%</font> premarket after its immunotherapy drug durvalumab was <a href=\"http://www.reuters.com/article/astrazeneca-cancer-idUSFWN1IE06Z?feedType=RSS&amp;feedName=companyNews\" target=\"_blank\">shown</a> to fight and reduce the risk of stage III lung cancer.</li><li>The chemotherapy alternative, called by brand name Imfinzi, is hoped to become a blockbuster drug with sales in the billions of dollars.</li><li>AstraZeneca intends to get regulatory approval \"as soon as possible.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3266792\" data-linked=\"AstraZeneca rises on Imfinzi results\" data-tweet=\"$AZN - AstraZeneca rises on Imfinzi results https://seekingalpha.com/news/3266792-astrazeneca-rises-on-imfinzi-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3266792-astrazeneca-rises-on-imfinzi-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":58,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}